{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:31:52Z","timestamp":1774567912637,"version":"3.50.1"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032668","name":"Kyowa Kirin International","doi-asserted-by":"crossref","award":["No"],"award-info":[{"award-number":["No"]}],"id":[{"id":"10.13039\/100032668","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>X-linked hypophosphataemia is a rare, genetic, lifelong disorder caused by phosphate-regulating endopeptidase homologue X-linked pathogenic variants and, if left untreated, is associated with a progressive accumulation of musculoskeletal manifestations. Burosumab is a fully human monoclonal antibody that targets circulating fibroblast growth factor 23 and directly inhibits its activity, thereby correcting the abnormal phosphate homoeostasis in people with X-linked hypophosphataemia (XLH). The efficacy and safety of burosumab has been demonstrated in a programme of clinical trials in children and adults. Few data describe the experience of adolescents with XLH receiving burosumab treatment before and after skeletal growth ends. This prospective, multicentre, mixed-methods study described the lived experience of adolescents with XLH treated with burosumab at the end of skeletal growth (NCT05181839). Using patient-reported outcomes, wearable devices, and interviews, we found low median symptom severity scores for pain (0.00), stiffness (0.00), and fatigue (1.75) on a 0\u201310 scale. Symptoms were usually triggered by physical activity but rarely interfered with daily life. Some adolescents reported emotional concerns related to XLH and treatment transition. These insights can inform patient support during transition to adult care.<\/jats:p>","DOI":"10.1371\/journal.pone.0344902","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:38:29Z","timestamp":1774028309000},"page":"e0344902","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysis"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3601-8942","authenticated-orcid":true,"given":"Vrinda","family":"Saraff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Arango","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Bacchetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-3222","authenticated-orcid":true,"given":"Annemieke M.","family":"Boot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Burren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amish","family":"Chinoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poonam","family":"Dharmaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-8939","authenticated-orcid":true,"given":"Maria Amelia G\u00f3mez","family":"Llorente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8863-2007","authenticated-orcid":true,"given":"Juan David Gonz\u00e1lez","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-6973","authenticated-orcid":true,"given":"Iva","family":"Gueorguieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elin Haf","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wesley","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Komarzynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor R\u00edos","family":"Duro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela J.","family":"Rylands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Sandilands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8537-5468","authenticated-orcid":true,"given":"Angela","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Hardie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santhani M.","family":"Selveindran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"7","key":"pone.0344902.ref001","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"TO Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"1","key":"pone.0344902.ref002","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"SS Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"pone.0344902.ref003","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey","volume":"3","author":"A Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"issue":"1","key":"pone.0344902.ref004","doi-asserted-by":"crossref","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"A Linglart","year":"2014","journal-title":"Endocr Connect"},{"issue":"1","key":"pone.0344902.ref005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","article-title":"Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review","volume":"32","author":"L Seefried","year":"2021","journal-title":"Osteoporos Int"},{"issue":"7","key":"pone.0344902.ref006","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s11136-020-02465-x","article-title":"Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study","volume":"29","author":"SH Lo","year":"2020","journal-title":"Qual Life Res"},{"issue":"8","key":"pone.0344902.ref007","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab070","article-title":"Patient-reported complications, symptoms, and experiences of living with X-linked hypophosphatemia across the life-course","volume":"5","author":"M Cheung","year":"2021","journal-title":"J Endocr Soc"},{"key":"pone.0344902.ref008","author":"N Ferizovic","year":"2019"},{"issue":"3","key":"pone.0344902.ref009","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz203","article-title":"Prevalence and mortality of individuals with x-linked hypophosphatemia: a United Kingdom real-world data analysis","volume":"105","author":"S Hawley","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"pone.0344902.ref010","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"D Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"pone.0344902.ref011","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia","volume":"107","author":"A Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"pone.0344902.ref012","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"MP Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10189","key":"pone.0344902.ref013","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"EA Imel","year":"2019","journal-title":"Lancet"},{"key":"pone.0344902.ref014","first-page":"1","article-title":"Benefits of long-term burosumab persist in 11 girls with X-linked hypophosphatemia (XLH) who transitioned into adolescence during the phase 2 CL201 trial","volume":"91","author":"ACT Boot","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"pone.0344902.ref015","article-title":"Defining a Growing and Maturing Skeleton and its Relevance in Diseases that Affect Skeletal Growth, Such as X-Linked Hypophosphataemia (XLH)","volume":"4","author":"B-N Signe","year":"2021","journal-title":"Int J Rare Dis Disord"},{"issue":"1","key":"pone.0344902.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295080","article-title":"A patient-centred and multi-stakeholder co-designed observational prospective study protocol: Example of the adolescent experience of treatment for X-linked hypophosphataemia (XLH)","volume":"19","author":"V Saraff","year":"2024","journal-title":"PLoS One"},{"key":"pone.0344902.ref017","volume-title":"Designing and conducting mixed methods research","author":"JW Creswell","year":"2017","edition":"9"},{"issue":"9","key":"pone.0344902.ref018","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2471\/BLT.07.043497","article-title":"Development of a WHO growth reference for school-aged children and adolescents","volume":"85","author":"M de Onis","year":"2007","journal-title":"Bull World Health Organ"},{"key":"pone.0344902.ref019","unstructured":"Garmin. Vivosmart 4 Owner\u2019s Manual: Earning Intensity Minutes. https:\/\/www8.garmin.com\/manuals\/webhelp\/vivosmart4\/EN-US\/GUID-02D2D4E7-4CEE-44C7-831C-2E5F58613B60.html. Accessed 2026 February 2."},{"issue":"1","key":"pone.0344902.ref020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s13023-022-02452-0","article-title":"Health-related quality of life of X-linked hypophosphatemia in Spain","volume":"17","author":"MIL Yanes","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"pone.0344902.ref021","volume-title":"Qualitative Research Practice: A Guide for Social Science Students and Researchers","author":"J Ritchie","year":"2014"},{"key":"pone.0344902.ref022","article-title":"PRO154 Confirmatory psychometric validation of the brief pain inventory (BPI-SF) in adult x-linked hypophosphatemia (XLH)","volume":"22","author":"A Skrinar","year":"2019","journal-title":"Value Health"},{"key":"pone.0344902.ref023","doi-asserted-by":"crossref","first-page":"104958","DOI":"10.1016\/j.ejmg.2024.104958","article-title":"Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets","volume":"70","author":"GI Baroncelli","year":"2024","journal-title":"Eur J Med Genet"},{"key":"pone.0344902.ref024","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1479-5868-8-78","article-title":"How many steps\/day are enough? for children and adolescents","volume":"8","author":"C Tudor-Locke","year":"2011","journal-title":"Int J Behav Nutr Phys Act"},{"issue":"11","key":"pone.0344902.ref025","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005263","article-title":"Physical Activity Guidelines for Americans From the US Department of Health and Human Services","volume":"11","author":"KL Piercy","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"pone.0344902.ref026","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jval.2022.07.005","article-title":"Quality-Adjusted Life Expectancy Norms for the English Population","volume":"26","author":"S McNamara","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"pone.0344902.ref027","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41746-022-00696-5","article-title":"Evaluation of physical health status beyond daily step count using a wearable activity sensor","volume":"5","author":"Z Xu","year":"2022","journal-title":"NPJ Digit Med"},{"issue":"1","key":"pone.0344902.ref028","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1186\/s12889-025-22256-8","article-title":"Longitudinal changes and tracking of in-school physical activity in primary school children: four-year longitudinal study","volume":"25","author":"K Sasayama","year":"2025","journal-title":"BMC Public Health"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:38:33Z","timestamp":1774028313000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344902"}},"subtitle":[],"editor":[{"given":"Gaetano Paride","family":"Arcidiacono","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0344902","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]}}}